CLINICAL_TRIALS trial_result · 2021-09-22

Clinical Trial Update: A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms [Phase 2]

Phase 2 clinical trial update for LY2140023 in schizophrenia patients with prominent negative symptoms has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Denovo Biopharma LLC | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2021-09-22